ArticleMolecular therapy. Methods & clinical development2022

A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer.

Shyambabu Chaurasiya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.